NTP Radioisotopes is a leading global producer and supplier of nuclear medicine and radiation-based products and services.

NTP is a state-owned public company, and is a subsidiary of the South African Nuclear Energy Corporation (Necsa).

Originally conceived in the early 1970s to supply the local South African market with commercial radiopharmaceuticals, NTP is now among the world’s top producers and distributors of key medical radioisotope molybdenum-99 (Mo-99), and radioisotope-based diagnostic imaging and therapy products including iodine-131 and lutetium-177.

NTP currently supplies up to a third of global demand for Mo-99, which is the most widely used medical isotope. The daughter or decay product of Mo-99, technetium-99m (Tc-99m), is used in more than 40-million medical diagnostic imaging studies every year.

Headquartered at Necsa’s Pelindaba enterprises complex in South Africa, NTP offers a uniquely integrated production, processing, packaging and delivery service, operating 24 hours a day to ensure the safe, rapid, and reliable delivery of radiopharmaceuticals to users around the world.

Our clients include global leaders in nuclear medicine imaging and diagnostics, such as Lantheus Medical Imaging, GE Healthcare, Mallinckrodt Pharmaceuticals, Nihon Medi-Physics, Jubilant DraxImage, IBA Molecular Imaging, HTA Co. Ltd, Samyoung Unitech, and the Eczacıbaşı-Monrol group.

NTP is also a leading supplier of high-quality irradiation services and radioactive sealed sources including caesium-137, iridium-192, and cobalt-60.

NTP is a Level 4 BBBEE contributor.